MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer

Rhea-AI Summary

MiMedx Group, Inc. (Nasdaq: MDXG) has appointed Kate Surdez as the new Chief Human Resources Officer (CHRO), effective July 18, 2022. With over 20 years of HR experience, Surdez has successfully led initiatives in talent acquisition and organizational change for major biotech companies. CEO Timothy Wright expressed confidence in Surdez's ability to enhance the company's talent strategies and alignment with business goals. MiMedx specializes in placental biologics, focusing on innovative treatments for chronic wounds and musculoskeletal conditions.

Positive

• Kate Surdez brings over 20 years of HR experience from successful biotech companies.
• Surdez previously played a critical role in an IPO and growth at Viela Bio.
• The addition of a CHRO indicates MiMedx's commitment to sustainable growth and talent development.

Negative

• None.

Proven Biotech Executive Brings Versatile Leadership Experience

MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today. Ms. Surdez comes to MIMEDX with more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organizational change management for several successful IPOs and large multinational biotech companies.

Timothy R. Wright, MIMEDX Chief Executive Officer, commented, “Kate is a seasoned executive with a passion for life sciences. She brings extensive experience in all elements of Human Resources and will be an influential part of advancing key business initiatives and talent strategies that align with our mission and objectives. I look forward to her contributions on our executive leadership team as we ensure MIMEDX remains a long-term destination for top talent, and a thriving environment for our employees.”

Throughout her career, Ms. Surdez has demonstrated valued leadership, a breadth of involvement in executive-level functions, and the ability to drive successful key partnerships across all levels of an organization. In addition, she has a recognized ability to translate an understanding of the business into actionable programs and company results in the people function. The Company has added the CHRO position to its leadership team to guide processes and programs that support sustainable growth.

“I am thrilled to join MIMEDX to contribute to the collective success of each and every employee,” Ms. Surdez added. “This is an extraordinary opportunity to be a part of an organization with industry-leading people, products and customer service that make a difference in the lives of patients.”

About Kate Surdez

Kate is an accomplished Human Resources (HR) leader who has managed several organizations through growth and transformation. She has held a variety of HR roles with increasing responsibility, most recently as the Head of HR for Vaxxinity, a clinical-stage biotech at which she built the HR function from the ground up. Prior thereto, she served as Senior Vice President of HR for Viela Bio, a successful biotech start-up spun out of AstraZeneca that was later acquired by Horizon Therapeutics. During her time at Viela Bio, she played a critical role in their IPO, developing infrastructure and the commercial organization and taking the company from 35 to 170 employees. Earlier in her career, Kate provided HR support to multiple functions within the biologics and small molecule teams at MedImmune/AstraZeneca, including as Global HR Lead at AstraZeneca. Kate holds a Bachelor of Arts in History from the University of North Carolina at Wilmington.

About MIMEDX

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts
Investors:
Jack Howarth
Investor Relations
404.360.5681
jhowarth@mimedx.com

Media:
Hilary Dixon
Corporate & Strategic Communications
404.323.4779
hdixon@mimedx.com

FAQ

Who is the new CHRO of MiMedx Group, Inc. (MDXG)?

Kate Surdez has been appointed as the new Chief Human Resources Officer.

What experience does Kate Surdez have in the biotech industry?

Kate Surdez has over 20 years of HR experience, including leading HR functions for several successful biotech IPOs.

What is the focus of MiMedx Group, Inc. (MDXG)?

MiMedx specializes in developing and distributing placental biologics for treating chronic wounds and musculoskeletal conditions.

When was Kate Surdez appointed as CHRO for MiMedx Group, Inc. (MDXG)?

Kate Surdez was appointed as CHRO on July 18, 2022.

How many allografts has MiMedx supplied?

MiMedx has supplied over two million allografts through various shipment methods.